Ibrutinib monotherapy is initially effective in a high fraction of patients with ABC-DLBCL, but resistance to BTK inhibitors develops rapidly, even in tumors addicted to BCR-dependent NF-kB activation, and progression-free survival is therefore very short (2 months) [33, 50]. Here, BTK is linked to diffuse large B-cell lymphoma.